Detection of anti-ribosome antibodies: a long story of lights and shadows.
Circulating autoantibodies against ribosomal proteins characterise a subset of patients with systemic lupus erythematosus. Following the identification of three phosphorylated proteins as the main ribosomal autoantigens recognised by these autoantibodies, several studies have been carried out in the last decade to set up a reliable and sensitive method of detecting anti-ribosome autoantibodies and disclosing their possible clinical relevance in the diagnosis and monitoring of symptoms and signs of the disease. Although a number of clinical associations have been proposed, contrasting results have emerged from these investigations. This review analyses the methodological problems linked with the various techniques used to detect anti-ribosome antibodies and provides a critical update of the clinical associations described in lupus patients to date.
Caponi
L
L
Laboratory of Specialised Clinical Analysis, Department of Experimental Pathology, University of Pisa, Pisa, Italy.
Giordano
A
A
Bartoloni
E Bocci
EB
Gerli
R
R
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis / Q000276:immunology*; D001324:Autoantigens / Q000032:analysis / Q000276:immunology*; D015415:Biomarkers / Q000032:analysis; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D011379:Prognosis; D012269:Ribosomal Proteins / Q000276:immunology*; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D000888:Antibodies, Anti-Idiotypic; D001324:Autoantigens; D015415:Biomarkers; D012269:Ribosomal Proteins